Shortening fraction of >= 27% by echocardiogram OR ejection fraction of >= 50% by multi-gated acquisition (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower, as determined by echocardiogram or multi-gated acquisition (MUGA) scan within 4 weeks of randomizationXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 30 days of day 1 of studyXx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, or ejection fraction of > 50% by echocardiogram or radionuclide angiogramXx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide studyXx_NEWLINE_xXCardiac ejection fraction (left ventricular ejection fraction [LVEF]) >= institutional lower limit of normal by multi gated acquisition scan (MUGA)/radionuclide ventriculogram (RVG) or echocardiogram (ECHO)Xx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, orXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) assessment must be performed within 90 days prior to randomization; (LVEF assessment performed by 2-dimensional [D] echocardiogram is preferred; however, multi gated acquisition [MUGA] scan may be substituted based on institutional preferences;) the LVEF must be >= 50% regardless of the cardiac imaging facility's lower limit of normalXx_NEWLINE_xXPatients must have a left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (ILLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) within 28 days prior to registrationXx_NEWLINE_xXPatient must have a normal cardiac ejection fraction by pretreatment multigated acquisition scan (MUGA) or echocardiogram within 4 weeks prior to registration (resting ejection fraction >= 40% or >= 5% increase with exercise), shortening fraction by echocardiogram >= 24%, or to within the normal range of values for the institutionXx_NEWLINE_xXPatients must have an echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 42 days prior to registration with a cardiac ejection fraction >= 45%Xx_NEWLINE_xXPatients must have an echocardiogram (ECHO) or a nuclear study (multi-gated acquisition scan [MUGA] or first pass) within 4 weeks (28 days) prior to registration to treatment and must not have a left ventricular ejection fraction (LVEF) < institutional lower limit of normal (LLN); if the LLN is not defined at a site, the LVEF must be > 50% for the patient to be eligibleXx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, orXx_NEWLINE_xXNew York Heart Association class I or less; ordinary physical activity does not cause undue fatigue, palpitations, dyspnea, or angina pain; patients 60 years or older must have a left ventricular ejection fraction (LVEF) at rest >= 40% measured by echocardiogram or multi-gated acquisition (MUGA)Xx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, orXx_NEWLINE_xXShortening fraction of >= 27% by echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) > lower limit of normal (LLN) based on cardiac echocardiography (ECHO) or multi-gated acquisition (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction > 50% as measured by echocardiogram or multi gated acquisition (MUGA) scanXx_NEWLINE_xXAdequate Cardiac Function defined as: Shortening fraction of ? 27% by echocardiogram, or Ejection fraction of ? 50% by radionuclide evaluation or echocardiogram.Xx_NEWLINE_xXLeft ventricular ejection fraction >= 50%, as determined by multigated acquisition (MUGA) or echocardiogram within 30 days prior to protocol registrationXx_NEWLINE_xXCardiac ejection fraction >= 50% (for HER2+ patients) as assessed by echocardiogram, multi gated acquisition scan (MUGA) scan, or cardiac magnetic resonance imaging (MRI)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO); ECHO scans must be used throughout the study when indicatedXx_NEWLINE_xXLeft ventricular ejection fraction >= 50% by transthoracic echocardiography or multi-gated acquisition scan (MUGA) within 28 days prior to the first dose of the study drugXx_NEWLINE_xXPatients must not have a cardiac ejection fraction < 45% or the presence of New York Heart Association stage III or IV heart failure within 14 days prior to registration; either echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) may be used to determine ejection fractionXx_NEWLINE_xXPatients must have left ventricular ejection fraction (LVEF) >= 50 as measured by echocardiogram or multigated acquisition scan (MUGA)Xx_NEWLINE_xXPatients with an ejection fraction < 50% assessed by multigated acquisition scan (MUGA) or echocardiogram (ECHO) scan within 7 days of day 1Xx_NEWLINE_xXCardiopulmonary dysfunction, including inadequate left ventricular ejection function at baseline, less than 50% by either echocardiogram or multiple-gated acquisition scanXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) determined by echocardiogram or multi-gated acquisition scan ? 50%Xx_NEWLINE_xXPatients with a cardiac ejection fraction (as measured by either Multi Gated Acquisition [MUGA] or echocardiogram [EKG]) < 40%Xx_NEWLINE_xXAbnormal cardiac function defined by a LVEF <50% by ECHO or MUGAXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by echocardiogram or multigated acquisition scan (MUGA) documented within 28 days prior to first dose of study drugXx_NEWLINE_xXParticipants with a history of chronic heart failure or significant cardiovascular disease must have an echocardiogram or multigated acquisition scan indicating left ventricular ejection fraction greater than or equal to 45% within 28 days prior to the first dose of study drug.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% by 2-dimensional (2D) echocardiogram (ECHO) or multigated acquisition (MUGA) scan; timeline: within 4 weeks prior to enrollmentXx_NEWLINE_xXCardiac function: Left ventricular ejection fraction (LVEF) > 40%; or LV shortening fraction > 26% by cardiac echocardiogram or by Multi Gated Acquisition Scan (MUGA).Xx_NEWLINE_xXBaseline ejection fraction ? 50% as assessed by echocardiogram or multi-gated acquisition (MUGA) scan.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) within 5 absolute percentage points of institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 28 days prior to study registration (i.e., if the institutional normal is 50%, subject’s LVEF may be as low as 45% to be eligible for the study)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) greater than 50% on echocardiography or multiple gated acquisition (MUGA) scanXx_NEWLINE_xXLeft ventricular ejection fraction of > 50% on baseline echocardiography or multi-gated acquisition (MUGA) scanXx_NEWLINE_xXLeft ventricular ejection fraction; LVEF >= 40% (by echocardiogram or multigated acquisition scan [MUGA] testing)Xx_NEWLINE_xXFor Part F (LY2835219 + trastuzumab):The participant must have received at least 1 chemotherapy regimen for metastatic disease and may be receiving ongoing therapy with trastuzumab. The participant must have an estimated left ventricular ejection fraction within the normal range by either echocardiogram or multigated acquisition (MUGA) scanXx_NEWLINE_xXFor Part H: (abemaciclib + trastuzumab + pertuzumab): The participant must have received at least 1 chemotherapy regimen for metastatic disease. The participant may be receiving ongoing therapy with trastuzumab and/or pertuzumab at the time of study entry. The participant must have an estimated left ventricular ejection fraction (LVEF) within the normal range by either echocardiogram or multigated acquisition (MUGA) scan.Xx_NEWLINE_xXNormal left ventricular ejection fraction of >= 50% estimated by multi gated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction >= 50% on echocardiogram or multi gated acquisition scan (MUGA) scanXx_NEWLINE_xXPatients with symptomatic left ventricular dysfunction or baseline left ventricular ejection fraction (LVEF) my multigated acquisition scan (MUGA) or echocardiogram (ECHO) of =< 50% are not eligibleXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% (determined by echocardiogram or multigated acquisition scan) within 42 days of treatmentXx_NEWLINE_xXEjection fraction of < 45% by either multi gated acquisition scan (MUGA) or echocardiogram (ECHO)Xx_NEWLINE_xXCardiac ejection fraction < 30% (or, if unable to obtain ejection fraction, shortening fraction < 26%) on multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (echo), symptomatic coronary artery disease, or other cardiac failure requiring therapy; patients with a history of, or current cardiac disease should be evaluated with appropriate cardiac studies and/or cardiology consult; patients with a shortening fraction of < 26% must be seen by cardiology for approvalXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) of 50% or greater, as measured by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan, within 28 days before the first dose of TAK-580Xx_NEWLINE_xXParticipants must have adequate cardiac function, e.g. left ventricular ejection fraction (LVEF) of > 50% as assessed by multi-gated acquisition (MUGA) or ultrasound/echocardiography (ECHO); corrected QT interval (QTc) < 470msXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ? 50% by echocardiogram (echo) or multigated acquisition (MUGA) scan within 28 days before day 1 of studyXx_NEWLINE_xXHave a left ventricular ejection fraction (LVEF) >45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scanXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 45% as determined by multi-gated acquisition scan (MUGA) or echocardiogram (ECHO).Xx_NEWLINE_xXOn echocardiogram, documented left ventricular ejection fraction > 45%; patients may instead have a multigated acquisition (MUGA) scan instead of transthoracic echocardiogram (TTE).Xx_NEWLINE_xXParticipant has a left ventricular ejection fraction (LVEF) <50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO);Xx_NEWLINE_xXBaseline left ventricular ejection fraction (LVEF) greater than or equal to (>=) 53 percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scansXx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Left ventricular ejection fraction (LVEF) >= 50% as determined by echocardiogram or multigated acquisition scan (MUGA)Xx_NEWLINE_xXEXPANDED ACCESS COHORT: Participants must have adequate cardiac function, defined as:\r\n* Left ventricular ejection fraction (LVEF) >= 50% as determined by echocardiogram (ECHO) or MUGA\r\n* QTcF =< 480 msec on screening electrocardiogram (ECG)Xx_NEWLINE_xXClinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality, including any of the following:\r\n* History of angina pectoris, symptomatic pericarditis, coronary artery bypass graft (CABG) or myocardial infarction within 6 months prior to study entry\r\n* Documented cardiomyopathy\r\n* Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) at screeningXx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide studyXx_NEWLINE_xXLeft ventricular cardiac ejection fraction of ?45% by echocardiogram or multigated acquisition (MUGA) scanXx_NEWLINE_xXPatients must have normal left ventricular systolic function, as demonstrated by a transthoracic echocardiogram or multi-gated acquisition scan (MUGA) scan showing a normal left ventricular ejection fractionXx_NEWLINE_xXCardiac: Left ventricular ejection fraction (LVEF) at rest ? 40%. For patients aged < 13 years, shortening fraction (SF) ? 26% by echocardiogram or Multi Gated Acquisition Scan (MUGA) may be substituted for LVEF.Xx_NEWLINE_xXLeft ventricular ejection fraction >= 45% by multigated acquisition scan (MUGA) or echocardiogramXx_NEWLINE_xXPatients must not have presence of class III or IV heart failure, according to New York Heart Association classifications, or a known left ventricular ejection fraction of less than 50%; Note: left ventricular ejection fraction (LVEF) evaluation by echocardiogram or multi-gated acquisition scan (MUGA) is not required prior to registrationXx_NEWLINE_xXLeft ventricular ejection fraction >= 40% by 2 dimensional (D) echocardiogram (ECHO) or multigated acquisition (MUGA) scan, or left ventricular shortening fraction >= 20% by ECHO for patients receiving MAC, RIC or RIC-MMF, or LVEF > 30%; if the patient has radiologic evidence of aortic, renal, or coronary artery vasculitis, LVEF >= 30% for patients receiving IOCXx_NEWLINE_xXNormal ejection fraction (echocardiogram [ECHO]) >= 53% (if a range is given then the upper value of the range will be used) or cardiac MRIXx_NEWLINE_xXNormal cardiac function, as determined by left ventricular ejection fraction (LVEF) >= institutional lower limit of normal on echocardiogram or multi-gated acquisition scan (MUGA) within 1 month of registrationXx_NEWLINE_xXEjection fraction < 40% obtained by either multi gated acquisition scan (MUGA) or echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) > 50% as assessed by echocardiogram or MUGA (multi gated acquisition scan)Xx_NEWLINE_xXShortening fraction > 28% by echocardiogram or Ejection Fraction of > 50 % by multigated acquisition (MUGA)Xx_NEWLINE_xXScreening calculated LVEF of ?50% by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scanXx_NEWLINE_xXNormal cardiac ejection fraction (> 50%) by multi gated acquisition scan (MUGA) or echocardiogramXx_NEWLINE_xXAdequate cardiac function defined as an ejection fraction of >= 50% by multi gated acquisition scan (MUGA) scan or echocardiogram and a corrected QT (QTc) interval of =< 450 ms for men and =< 460 ms for womenXx_NEWLINE_xXBaseline multi-gated acquisition scan (MUGA) or echocardiogram scans with left ventricular ejection fraction (LVEF) of > 50%.Xx_NEWLINE_xXPatients with a cardiac ejection fraction (as measured by either multi-gated acquisition [MUGA] or echocardiogram) < 40%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) must be equal to or greater than 50%, as measured by multigated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXEjection fraction measured by echocardiogram or multigated acquisition (MUGA) >= 50%Xx_NEWLINE_xXBaseline multigated acquisition scan (MUGA) or echocardiogram (ECHO) done only in subjects with prior doxorubicin exposure. The test must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normalXx_NEWLINE_xXA cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of >= 50% established by multi-gated acquisition scan (MUGA) or echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) as assessed by either multigated acquisition (MUGA) scan or echocardiogram (ECHO)Xx_NEWLINE_xXHave current or a history of congestive heart failure New York Heart Association (NYHA) class 3 or 4, or any history of documented diastolic or systolic dysfunction (left ventricular ejection fraction [LVEF] < 40%, as measured by multigated acquisition [MUGA] scan or echocardiogram)Xx_NEWLINE_xXEjection fraction < 50% on screening echocardiography (ECHO) or multigated acquisition scan (MUGA).Xx_NEWLINE_xXCardiac ejection fraction within institutional normal limits by either multigated acquisition scan (MUGA) or echocardiogram (ECHO) at baselineXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) above institutional lower limit of normal (by echocardiogram or multi-gated acquisition [MUGA] scan within 90 days of registration)Xx_NEWLINE_xXIf the participant is to be enrolled in the doxorubicin combination arm, a left ventricular dysfunction (LVEF < 50%) or shortening fraction of <27% by echocardiogram (either multigated acquisition [MUGA] or echocardiogram [ECHO] are required, not both).Xx_NEWLINE_xXMust be hemodynamically stable at the time of ET190L1-ARTEMIS T cell administration and have left ventricular ejection fraction (LVEF) ? 45% confirmed by echocardiogram or multigated acquisition scan (MUGA) scanXx_NEWLINE_xXLeft ventricular ejection fraction determined by echocardiogram or multiple-gated acquisition scan (MUGA) (cardiac scan) must be 50% or higherXx_NEWLINE_xXShortening fraction >= 28% by echocardiogram OR ejection fraction of >= 50 % by multigated acquisition (MUGA)Xx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, ORXx_NEWLINE_xXEjection fraction of >= 50% by gated radionuclide study/echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF as determined by cardiac echo or MUGA scan) below the normal limits of the institutions specific testing range. This assessment may be repeated once at the discretion of the Investigator with the approval of the Sponsor.Xx_NEWLINE_xXWithin 4 weeks before enrollment: Left ventricular ejection fraction (LVEF) > 45% by multigated acquisition (MUGA) or rest echocardiogram (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) > 40% or LV shortening fraction > 26% by cardiac echocardiogram or by multi-gated acquisition (MUGA) scanXx_NEWLINE_xXAdequate cardiac function, defined as left ventricular ejection fraction (LVEF) of >= 50% as assessed by echocardiogram or multigated acquisition (MUGA) scan, or LVEF of 45-49% and clearance by a cardiologistXx_NEWLINE_xXAdequate cardiac function, defined as left ventricular ejection fraction (LVEF) of ? 50% as assessed by echocardiogram or MUGA scan, or LVEF of 45-49% and clearance by a cardiologist; if subject receives cardiotoxic chemotherapy after enrollment, repeat echocardiogram or MUGA is required to reestablish eligible LVEFXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ? 55% at rest (multigated acquisition [MUGA] scan or echocardiogram [Echo])Xx_NEWLINE_xXLeft ventricular ejection fraction greater than (>) 50% as measured by ECHO or MUGA scan within 4 weeks before receiving the first dose of study drug.Xx_NEWLINE_xXHas left ventricular ejection fraction (LVEF) < 45% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan.Xx_NEWLINE_xXShortening fraction >= 28% by echocardiogram or ejection fraction of >= 50 % by multigated acquisition (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiography (ECHO) or multigated acquisition (MUGA)Xx_NEWLINE_xXCardiac echocardiogram, stress test, or multigated acquisition (MUGA) within past 6 months with demonstrated left ventricular ejection fraction (LVEF) > 50%Xx_NEWLINE_xXPatients with New York Heart Association (NYHA) class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) < 40% by echocardiogram or multi-gated acquisition (MUGA) scanXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40% by echocardiography, multigated acquisition (MUGA), or cardiac magnetic resonance imaging (MRI); no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities (within 28 days of study registration)Xx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram ORXx_NEWLINE_xXLeft ventricular ejection fraction >= 50% measured by multigated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXIf a patient has received anthracycline chemotherapy after prior enrollment on PLAT-02, they must have an echocardiogram to demonstrate shortening fraction > 28% or multigated acquisition scan (MUGA) to demonstrate ejection fraction of > 50%; the echocardiogram or MUGA can be done at any time following the anthracycline (does NOT need to be within 48 hours of the T cell infusion)Xx_NEWLINE_xXShortening fraction > 28% by echocardiogram or ejection fraction of > 50 % by MUGAXx_NEWLINE_xXEjection fraction measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)\r\n> 50%.Xx_NEWLINE_xXLeft ventricular ejection fraction of 50% or more at baseline (by echocardiography or multiple-gated acquisition scanning)Xx_NEWLINE_xX(For cohort B): Baseline multigated acquisition (MUGA) or echocardiogram showing left ventricular ejection fraction (LVEF) >= 50% within 6 weeks prior to initiation of NACTXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram (ECHO) or multiple uptake gated acquisition (MUGA) scan performed within 1 month before starting lymphodepleting chemotherapyXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) assessment by 2-dimensional (D) echocardiogram or multi-gated acquisition (MUGA) scan performed within 90 days prior to registration must be >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)Xx_NEWLINE_xXSymptomatic congestive heart failure (New York Heart Association III-IV) or documented cardiomyopathy with left ventricular ejection fraction (LVEF) <50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening. MUGA/ ECHO to be performed within 28 days prior to registration.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA)Xx_NEWLINE_xXImpaired cardiac function (left ventricular ejection fraction [LVEF] < 40%) as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scanXx_NEWLINE_xXLeft ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi-gated acquisition (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40% by echocardiography or multi-gated acquisition scan (MUGA) or cardiac magnetic resonance imaging (MRI), no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalitiesXx_NEWLINE_xXImpaired cardiac function (left ventricular ejection fraction [LVEF] < 40%) as assessed by echocardiography (ECHO) or radionuclide ventriculogram (MUGA) scanXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF as determined by cardiac echo or MUGA scan) below the normal limits of the institutions specific testing range. This assessment may be repeated once at the discretion of the Investigator with the approval of the Sponsor.Xx_NEWLINE_xXCardiac ejection fraction >= 50%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO) or multiple-gated acquisition (MUGA), and no clinically significant electrocardiography (ECG) findingsXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40% by echocardiography or multi-gated acquisition scan (MUGA), no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalitiesXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >/= 50 percent (%) on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)Xx_NEWLINE_xXAdequate cardiac function defined as an ejection fraction on echocardiogram (ECHO) or multi-gated acquisition (MUGA) that is at or above the institutional normal limitsXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) within 5 absolute percentage points of institutional standard of normal (50-70%) as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration (ie, if the institutional normal is 50%, subject’s LVEF may be as low as 45% to be eligible for the study)Xx_NEWLINE_xXCELL PROCUREMENT: Subjects must not have left ventricular ejection fraction of < 40% (shortening fraction < 27% for pediatric subjects) as measured by echocardiogram or multi-gated acquisition (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45%, assessed within 3 months prior to registration, e.g. by multigated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modalityXx_NEWLINE_xXEjection fraction of >= 50% by echocardiogram or multi-gated acquisition (MUGA) scanXx_NEWLINE_xXAbsence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 40%; for children that are not able to cooperate with multi-gated acquisition (MUGA) and echocardiography, such should be clearly stated in the physician’s noteXx_NEWLINE_xXPatient has no significant ischemic heart disease or myocardial infarction (MI) within 6 months before the first dose of TVB 2640 and currently has adequate cardiac function, as evidenced by a left ventricular ejection fraction (LVEF) of >= 50% as assessed by multi-gated acquisition (MUGA) or ultrasound/echocardiography (ECHO); and corrected QT interval (QTc) < 470 msec on screening electrocardiogram (EKG)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) assessment (i.e., 2 dimensional [2-D] echocardiogram or multi-gated acquisition [MUGA] scan) performed within 12 weeks prior to study registration indicates an LVEF >= 50% regardless of the cardiac imaging facility’s lower limit of normalXx_NEWLINE_xXPatients must have a shortening fraction >= 27% or left ventricular ejection fraction >= 50% measured by echocardiogram (ECHO) or measured by multiple-gated acquisition scans (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) of lesser than [<] 50 percent (%) as determined by multiple uptake gated acquisition (MUGA) or echocardiography during screeningXx_NEWLINE_xXA cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of 50% established by multi-gated acquisition scan (MUGA) or echocardiogramXx_NEWLINE_xXCardiac ejection fraction >= 45% by echocardiogram (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45% by multi-gated acquisition scan (MUGA) or rest echocardiogram (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% by transthoracic echocardiogram or multigated acquisition scan (MUGA)Xx_NEWLINE_xXEjection fraction > 45% by either multi-gated acquisition scan (MUGA) scan or echocardiogramXx_NEWLINE_xXPatients have left ventricular ejection fraction (LVEF) >= 50% by multigated acquisition scan (MUGA) or echocardiogram before study randomizationXx_NEWLINE_xXBaseline left ventricular ejection fraction of at least 40% by multigated acquisition (MUGA) or echocardiography (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) at rest >= 40%; for patients aged < 13 years, shortening fraction (SF) >= 26% by echocardiogram or LVEF by multigated acquisition scan (MUGA) may be usedXx_NEWLINE_xXMulti-gated acquisition (MUGA) scan or echocardiogram (ECHO) >= ejection fraction (EF) of 50%Xx_NEWLINE_xXShortening fraction > 28% by echocardiogram orXx_NEWLINE_xXLeft ventricular ejection fraction >= 45%, assessed within 3 months prior to study day 0, e.g. by multi gated acquisition scan (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failureXx_NEWLINE_xXBaseline (pre-HCT) multi-gated acquisition (MUGA) or echocardiography (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of normal (LLN) of the institutional normalXx_NEWLINE_xXAbsence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction >= 40%; for children that are not able to cooperate with multi-gated acquisition scan (MUGA) and echocardiography, such should be clearly stated in the physician’s noteXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) of the institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administrationXx_NEWLINE_xXLeft ventricular ejection fraction >= 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within 6 months of study entryXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 50% as determined by multigated acquisition (MUGA) scan or electrocardiogram (ECHO), or uncontrolled hypertension (refer to World Health Organization-International Society of Hypertension [WHO-ISH] guidelines)Xx_NEWLINE_xXAdequate cardiac function, defined as left ventricular ejection fraction (LVEF) >= 35% as assessed by echocardiogram (ECHO) or multiple uptake gated acquisition (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 50 as determined by multi gated acquisition scan (MUGA) scan or echocardiography (ECHO)Xx_NEWLINE_xXMulti-gated acquisition scan (MUGA) or echocardiogram (ECHO) for left ventricular ejection fraction (LVEF) >= 45%Xx_NEWLINE_xXLeft ventricular ejection fraction >= 40% as confirmed by echocardiogram (ECHO)/multi gated acquisition scan (MUGA)Xx_NEWLINE_xXAdequate cardiac function as defined by the following:\r\n* Left ventricular ejection fraction (LVEF) >= 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram\r\n* Corrected QT interval (QTc) interval =< 480 ms (preferably the mean from triplicate electrocardiogram [ECG’s])Xx_NEWLINE_xXCardiac function >= international lower limit of normal (ILLN), e.g., left ventricular ejection fraction (LVEF) of > 50% as assessed by multi gated acquisition scan (MUGA) or echocardiography (ECHO), corrected QT interval (QTc) < 470 msXx_NEWLINE_xXBaseline multi-gated acquisition (MUGA) or echocardiogram showing left ventricular ejection fraction (LVEF) >= 50% within 6 weeks prior to initiation of neoadjuvant chemotherapyXx_NEWLINE_xXLeft ventricle ejection fraction (LVEF) >= 40% confirmed by echocardiography (ECHO)/ multi gated acquisition scan (MUGA)Xx_NEWLINE_xXBaseline multi gated acquisition scan (MUGA) or echocardiogram scans with left ventricular ejection fraction (LVEF) of > 50%Xx_NEWLINE_xXEjection fraction (EF) >= 50% on multi gated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study within 7 days prior to enrollmentXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) lower limit of normal (LLN) as assessed by either multigated acquisition (MUGA) scan or echocardiogram (ECHO)Xx_NEWLINE_xXHas a shortening fraction of >27% or an ejection fraction of ?50% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan and New York Heart Association (NYHA) Class ?2Xx_NEWLINE_xXEchocardiogram must have a shortening fraction or an ejection fraction greater than institutional lower limit of normal for age and gender; echocardiogram must be obtained while patient is not receiving cardiotropic medications (eg., pressors or afterload reducers)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA)Xx_NEWLINE_xXEjection fraction of > 40% by multigated acquisition (MUGA) or echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (by transthoracic echocardiography [TTE], multigated acquisition scan [MUGA] or cardiac magnetic resonance imaging [MRI]) sufficient to safely administer mitoxantrone as determined by the treating physicianXx_NEWLINE_xXBaseline multi-gated acquisition (MUGA) scan or echocardiogram showing left ventricular ejection fraction (LVEF) >= 50% at least 6 weeks prior to initiation of NACTXx_NEWLINE_xXEjection fraction measured by echocardiogram or multigated acquisition scan (MUGA) >= 50%Xx_NEWLINE_xXCardiac ejection fraction >= 40% (by either echocardiogram [ECHO] or multigated acquisition [MUGA])Xx_NEWLINE_xXCardiac ejection fraction >= 50% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)Xx_NEWLINE_xXIf prior history of ischemic heart disease or exposure to 200 mg/m^2 of doxorubicin, patients must have a measured ejection fraction (either by multigated acquisition scan [MUGA], echocardiogram [ECHO], stress test, or ventriculography) of at least 45%Xx_NEWLINE_xXPatients with a cardiac ejection fraction (as measured by either multi-gated acquisition [MUGA] scan or echocardiogram) < 40%; (Note: patients who have had prior anthracycline exposure of > 250 mg/m^2 may be eligible after discussion with the principal investigator [PI])Xx_NEWLINE_xXFor children with neuroblastoma (NBL): normal ejection fraction (> 55%) documented by echocardiogram or radionuclide multi-gated acquisition (MUGA) evaluation OR normal fractional shortening (> 27%) documented by echocardiogram; for subjects with paraganglioma/ pheochromocytoma: no clinically significant cardiac dysfunctionXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) or magnetic resonance imaging (MRI) >= 40%Xx_NEWLINE_xXCardiac ejection fraction of >= 50% by echocardiogram or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXPatients must have normal cardiac function, as evidenced by a left ventricular ejection fraction (LVEF) within institutional normal limits; echocardiogram may be used if multi gated acquisition (MUGA) scan is not available, but the same test must be used throughout the study to evaluate LVEFXx_NEWLINE_xXShortening fraction > 28% by echocardiogram or an ejection fraction > 50% by multigated acquisition scan (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (Echo) or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% by echocardiogram (ECHO) or multi gated acquisition (MUGA) scanXx_NEWLINE_xXThe left ventricular ejection fraction (LVEF) assessment by 2-D echocardiogram or multi-gated acquisition (MUGA) scan performed within 90 days prior to study entry must be greater than or equal to 50% regardless of the facility's lower limit of normal (LLN).Xx_NEWLINE_xXCardiac ejection fraction > 50% (for HER2+ patients) as assessed by echocardiogram, multigated acquisition (MUGA) scan, or cardiac magnetic resonance imaging (MRI)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) of 50% or above, by multigated acquisition scan (MUGA) or echocardiogramXx_NEWLINE_xXEjection fraction measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) >= 50%Xx_NEWLINE_xXEjection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 45% (evaluation within 6 weeks of screening does not need to be repeated)Xx_NEWLINE_xXLeft ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXIf the research participant is to undergo leukapheresis, he/she must have ejection fraction measured by echocardiogram or multigated acquisition scan (MUGA) > 45% (within 6 weeks of time of screening)Xx_NEWLINE_xXCardiac ejection fraction >= 40% (by either cardiac echocardiogram [echo] or multi gated acquisition [MUGA] scan); documentation of recent (=< 6 months from screening) outside reports is acceptableXx_NEWLINE_xXEjection fraction >=40% by transthoracic echocardiogram or radionuclide ventriculogram, i.e. multigated acquisition (MUGA) scanXx_NEWLINE_xXEchocardiogram (ECHO) or multi gated acquisition scan (MUGA): ejection fraction of >= 50% AND no finding of abnormal wall motion (i.e. report does not indicate that wall motion is “abnormal” or “altered”)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) greater than or equal to 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram (Phase II only)Xx_NEWLINE_xXLeft ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXNormal cardiac function as defined by a normal ejection fraction by multi gated acquisition scan (MUGA) or echocardiogramXx_NEWLINE_xXAdequate cardiac function (ejection fraction [EF] > 50%) based on multi gated acquisition (MUGA) scan or 2 dimensional-echocardiogram (2D-Echo)Xx_NEWLINE_xXLeft ventricle ejection fraction (LVEF) >= 40% confirmed by echocardiogram (ECHO)/multi gated acquisition (MUGA) scanXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40%; 2-dimension (D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multi gated acquisition scan (MUGA) is acceptable if ECHO is not availableXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% by MUGA (multi gated acquisition) scan or echocardiogramXx_NEWLINE_xXPatients must have adequate cardiac function (left ventricular ejection fraction [LVEF]) >= 50% as determined by a multigated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXPatients must have normal baseline cardiac function based upon echocardiogram or gated blood pool scan (multigated acquisition scan [MUGA]) with an ejection fraction >= 50%Xx_NEWLINE_xXCardiac ejection fraction (EF) >= 45% by 2-dimensional echocardiogram (2D-ECHO) within 3 months of study entry (or within 1 month if received chemotherapy within the past 3 months)Xx_NEWLINE_xXBaseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normalXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) =< 50% as documented by multi gated acquisition scan (MUGA) or echocardiogram performed within 28 days prior to the first study treatmentXx_NEWLINE_xXLeft ventricular ejection fraction (EF) > 40% by echocardiogram, multigated acquisition scan (MUGA), or cardiac magnetic resonance (MR)Xx_NEWLINE_xXNo cardiac (left ventricular ejection fraction [LVEF] > 50% by multigated acquisition scan [MUGA] or three-dimensional echocardiography [TTE]; if LVEF > 40% but < 50% by MUGA or TTE MUST HAVE cardiology evaluation and clearance for ASCT)Xx_NEWLINE_xXCardiac ejection fraction of >= 50% by echocardiogram or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) or other similar cardia imaging performed within 1 month of treatmentXx_NEWLINE_xXHave a left ventricular ejection fraction (LVEF) >45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scanXx_NEWLINE_xXAdequate cardiac function as demonstrated by left ventricular ejection fraction (LVEF) of 45% or greater, by multiple gated acquisition (MUGA) or echocardiogram; no ongoing cardiac issues such as uncontrolled arrhythmias or unstable angina or congestive heart failureXx_NEWLINE_xXPatients must obtain a base line echocardiogram or multi gated acquisition scan (MUGA) and require the left ventricular ejection fraction to be within normal limits (or 50% or higher)Xx_NEWLINE_xXPatients with a cardiac ejection fraction (as measured by either multigated acquisition scan [MUGA] or echocardiogram) < 40% are excludedXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) > lower limit of normal (LLN) on multi gated acquisition scan (MUGA)Xx_NEWLINE_xXCardiac ejection fraction >= 50% by multiple gate acquisition (MUGA) scan and/or by echocardiogramXx_NEWLINE_xXAdequate cardiac reserve with a cardiac ejection fraction within the lower limit of facility normal by MUGA, or 50% by echocardiogramXx_NEWLINE_xXCardiac dysfunction documented by an ejection fraction less than the lower limit of the facility normal by multi-gated acquisition (MUGA) scan, or less than 50% by echocardiogramXx_NEWLINE_xXShortening fraction > 25% by echocardiogram or ejection fraction above the institutional lower limit of normal by multi gated acquisition scan (MUGA)Xx_NEWLINE_xXThe patient must be free of symptoms of uncontrolled cardiac disease, and must not have compromised cardiac function detected by echocardiogram (ECHO) or by gated cardiac blood flow scan (multi gated acquisition scan [MUGA]) left ventricular ejection fraction [LVEF] > 45%)Xx_NEWLINE_xXShortening fraction of >= 27% by echocardiogramXx_NEWLINE_xXMulti gated acquisition scan (MUGA) > 45% injection fractionXx_NEWLINE_xXAdequate cardiac function (left ventricular ejection fraction [LVEF] >= 40%) as assessed by echocardiography (ECHO) or multigated acquisition (MUGA) scan performed within 1 month of treatmentXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45% by multi gated acquisition scan (MUGA)/echocardiogram (ECHO)Xx_NEWLINE_xXCardiac: absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction >= 35%; for children that are not able to cooperate with multi gated acquisition scan (MUGA) and echocardiography, such should be clearly stated in the physician’s noteXx_NEWLINE_xXNo active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year; if multi gated acquisition (MUGA) is obtained, the left ventricular ejection fraction (LVEF) should exceed 40%Xx_NEWLINE_xXLeft ventricular ejection fraction ? 50% by echocardiogram or multiple gated acquisition scan.Xx_NEWLINE_xXAbsence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 45%; for children not able to cooperate with multigated acquisition (MUGA) or echocardiography, such should be clearly stated in the physician’s documentationXx_NEWLINE_xXCardiac ejection fraction (LVEF) by multiple gated acquisition scan (MUGA) less than the institutional lower limit of normal.Xx_NEWLINE_xXHistory of serious ventricular arrhythmia (ventricular tachycardia [VT] or ventricular fibrillation [VF], greater than or equal to 3 beats in a row); QTc greater than or equal to 450 msec for men and 470 msec for women; or left ventricular ejection fraction (LVEF) less than or equal to 40% by multi-gated acquisition scan (MUGA).Xx_NEWLINE_xXPatients must have a baseline left ventricular ejection fraction (LVEF) measured by multi-gated acquisition scan (MUGA) equal to or greater than the lower limit of normal for the radiology facility and if there are two consecutive MUGAS performed while on trastuzumab from the same radiology facility, there cannot be a decrease in LVEF of > 15% from the original MUGA scanXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) assessment must be performed within 6 weeks prior to randomization; (LVEF assessment performed by echocardiogram is preferred; however, multigated acquisition scan (MUGA) scan may be substituted based on institutional preferences); the LVEF must be >= 55% regardless of the cardiac imaging facility's lower limit of normalXx_NEWLINE_xXLeft ventricular ejection fraction ? 45%, assessed within 12 months prior to study day 0, e.g. by multigated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failureXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% measured by multigated acquisition (MUGA) scan, echo, or stress test study with myocardial perfusion imagingXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45% as determined by a multigated acquisition (MUGA) scan or echocardiogram, and QTc interval =< 480msXx_NEWLINE_xXNormal ejection fraction (>= 55%) documented by either echocardiogram or radionuclide MUGA evaluation OR normal fractional shortening (>= 27%) documented by echocardiogramXx_NEWLINE_xXSignificant cardiovascular abnormalities as defined by any one of the following: a. congestive heart failure, b. clinically significant hypotension, c. symptoms of coronary artery disease, d. presence of cardiac arrhythmias on electrocardiography (EKG) requiring drug therapy, e. ejection fraction < 50 % (echocardiogram or multigated acquisition scan [MUGA]).Xx_NEWLINE_xXWithin 14 days of study registration (30 days for pulmonary and cardiac): left ventricular ejection fraction (LVEF) >= 40% by echocardiography or multigated acquisition (MUGA), no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalitiesXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 3 weeks prior to starting study therapyXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45% at rest (multi gated acquisition [MUGA] or echocardiogram [ECHO])Xx_NEWLINE_xXTo be performed within 28 days prior to day 1 of protocol therapy: Left ventricular ejection fraction >= 50% as determined by multigated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% calculated by echocardiogram (ECHO) or multigated acquisition scan (MUGA)Xx_NEWLINE_xXCardiac ejection fraction >= 45% or within institutional normal limits; a nuclear medicine gated blood pool examination is preferred; a two-dimensional (2-D) echocardiogram (ECHO) scan is acceptable if a calculated ejection fraction is obtained and follow-up measurement of the cardiac ejection fraction will also be performed by echocardiography; measurement of cardiac ejection fraction should be within two weeks prior to receiving treatment\r\n* NOTE: when a multi gated acquisition scan (MUGA) or echocardiogram cannot be obtained due to weekend or holiday, then patients may be enrolled provided there is no history of significant cardiovascular disease and a measurement of cardiac ejection fraction will be performed within 5 days of study enrollmentXx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, orXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) assessment (eg, echocardiogram, radionuclide ventriculogram scan [MUGA], first-pass technique) performed within 3 months prior to initiation of study treatment indicates an LVEF of >= 50%Xx_NEWLINE_xXShortening fraction >= 28% by echocardiogram or ejection fraction >= 50% by echocardiogram or radionuclide studyXx_NEWLINE_xXEjection fraction (EF) >= 50% by multigated acquisition (MUGA) or echocardiography (ECHO) within 4 weeks prior to first dose of study treatmentXx_NEWLINE_xXLeft ventricular systolic dysfunction, defined as ejection fraction below institutional normal by echocardiography or multi-gated acquisition scan (MUGA); or current or past clinical diagnosis of congestive heart failure; history of ejection fraction decreased to below institutional normal or decrease of greater than 15% attributable to past trastuzumab or pertuzumab therapyXx_NEWLINE_xXAdequate cardiac function:\r\n* Left ventricular ejection fraction (LVEF) >= 50% as determined by multigated acquisition (MUGA) scan or echocardiogram (echo)\r\n* Corrected QT (QTc) interval =< 480 msXx_NEWLINE_xXLeft ventricular ejection fraction (EF) > 40% by echocardiogram, multi-gated acquisition (MUGA), or cardiac magnetic resonance (MR)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 40% as measured by echocardiogram or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, orXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45% at rest (multigated acquisition scan [MUGA] or echocardiogram [Echo])Xx_NEWLINE_xXCardiac function:\r\n* Normal ejection fraction (>= 55%) documented by either echocardiogram or radionuclide multi gated acquisition scan (MUGA) evaluation; OR \r\n* Normal fractional shortening (>= 27%) documented by echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) > 40% as assessed by echocardiogram or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXShortening fraction >= 27% by echocardiogram, orXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) documented within four weeks prior to first dose of study drug; adequate cardiac reserve ejection fraction (EF) >= 50%Xx_NEWLINE_xXPatients must have multigated acquisition (MUGA)/echocardiogram performed within 28 days prior to sub-study registrationXx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide studyXx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram or ejection fraction of >= 50% by gated radionuclide studyXx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide studyXx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide studyXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 0.4 by multi gated acquisition scan (MUGA) or echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) =< 55% as determined by multi gated acquisition (MUGA) scan or echocardiogram (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% at baseline as determined by either echocardiogram (ECHO) or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXEjection fraction (EF) measured by two-dimensional echocardiogram (2D-ECHO) or multigated acquisition scan (MUGA) scan of >= 45%Xx_NEWLINE_xXEchocardiogram or multi gated acquisition (MUGA) scan demonstrating an ejection fraction >= 45%Xx_NEWLINE_xXBaseline multigated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 45%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% by echocardiogram (ECHO) or multigated acquisition scan (MUGA); same method as used at baseline must be use throughout the study, ECHO is the preferred methodXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) assessment must be performed within 90 days prior to randomization; (LVEF assessment performed by 2-dimensional [2-D] echocardiogram is preferred; however, multi gated acquisition scan [MUGA] scan may be substituted based on institutional preferences); the LVEF must be >= 50% regardless of the cardiac imaging facility's lower limit of normal; note: since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments, it is critical that this baseline study be an accurate assessment; if the baseline LVEF is > 65%, the investigator is encouraged to have the accuracy of the initial LVEF result confirmed and repeat the test if the accuracy is uncertainXx_NEWLINE_xXBaseline (< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (multi gated acquisition scan [MUGA] scan) or echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) greater than or equal to institutional/laboratory lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXPatients must have either echocardiogram (ECHO) with ejection fraction >= 45% within 28 days prior to registrationXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multigated acquisition (MUGA) > 40%Xx_NEWLINE_xXEjection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 50%Xx_NEWLINE_xXAdequate cardiac function as defined by either of the following:            \r\n* An echocardiogram demonstrating an ejection fraction within normal limits\r\n* A multi gated acquisition (MUGA) scan demonstrating an ejection fraction within normal limitsXx_NEWLINE_xXFor patients on Part B: shortening fraction of >= 27% by echocardiogram or ejection fraction of >= 50% by gated radionuclide studyXx_NEWLINE_xXCardiac function: left ventricular ejection fraction >= 40% by multi gated acquisition scan (MUGA) or cardiac magnetic resonance imaging (MRI), or fractional shortening >= 28% by echocardiogram (ECHO)or left ventricular ejection fraction >= 50% by ECHOXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= institutional lower limit of normal (ILLN) (by echocardiogram [ECHO] or multi gated acquisition scan [MUGA])Xx_NEWLINE_xXEjection fraction (EF) by multigated acquisition scan (MUGA) or 2-dimensional (2-D) echocardiogram within institution normal limits; in case of low EF, the subject may remain eligible after a stress echocardiogram is performed if the EF is more than 35% and if the increase in EF with stress is estimated at 10% or moreXx_NEWLINE_xXPatients must have a cardiac ejection fraction > 45% on two-dimensional (2D) echocardiography or multi gated acquisition scan (MUGA) obtained within 28 days of study enrollmentXx_NEWLINE_xXLeft ventricular ejection fraction >= 45% by multigated acquisition scan (MUGA) or echocardiogram (ECHO), fractional shortening >= 28% by ECHOXx_NEWLINE_xXEjection fraction (EF) by multiple gated acquisition scan (MUGA) or 2-dimensional (D) echocardiogram within institution normal limits; in case of low EF, the subject may remain eligible after a stress echocardiogram is performed if the EF is more than 35% and if the increase in EF with stress is estimated at 10% or moreXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= institutional lower limit of normal by cardiac echocardiogram (echo) or multi gated acquisition (MUGA) scan within 56 days prior to step 2 registrationXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) that is at or above the lower institutional limits of normal, as assessed by multiple gated acquisition (MUGA) scan or echocardiogram within the 6 weeks prior to registrationXx_NEWLINE_xXLeft ventricular ejection fraction at or above institutional lower limit of normal (obtained within 8 weeks of registration by multigated acquisition [MUGA] scan or echocardiogram; the same test performed at baseline should be repeated after every 3 cycles of therapy)Xx_NEWLINE_xXAmerican Heart Association class I: patients with cardiac disease but without resulting limitation of physical activity; ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain; additionally, patients > 60 years of age must have a left ventricular ejection fraction of at least >= 40% demonstrated by multi gated acquisition scan (MUGA) or echocardiogram (Echo)Xx_NEWLINE_xXCardiac ejection fraction < 30% or, if unable to obtain ejection fraction, shortening fraction of < 26%) on multi-gated acquisition (MUGA) scan or cardiac echo, symptomatic coronary artery disease, other cardiac failure requiring therapy; patients with a history of, or current cardiac disease should be evaluated with appropriate cardiac studies and/or cardiology consult; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologistXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45%, preferably by 2-dimensional (D) echocardiogram (echo), or by multiple gated acquisition scan (MUGA); however, patients with LVEF of between 35% and 44% may also be eligible provided that such patients are cleared by a cardiology consultation; in such cases, cardiology will determine whether it is appropriate to perform a cardiac stress testXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) > 40% (multi gated acquisition scan [MUGA] or echocardiogram) normal per institutional standardXx_NEWLINE_xXPoor cardiac function: left ventricular ejection fraction < 50% as determined by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) or a shortening fraction below 27%Xx_NEWLINE_xXHas a shortening fraction of >27% or an ejection fraction of ?50% by echocardiogram or multi-gated acquisition scanXx_NEWLINE_xXPatients must have a left ventricular ejection fraction (LVEF) >= 50% by echocardiogram or multiple gated acquisition (MUGA) scan within 42 days prior to registrationXx_NEWLINE_xXPatients must not have presence of class III or IV heart failure, according to New York Heart Association classifications, or a known left ventricular ejection fraction of less than 50%; Note: left ventricular ejection fraction (LVEF) evaluation by echocardiogram or multi-gated acquisition scan (MUGA) is not required prior to registrationXx_NEWLINE_xXPatients must have a cardiac ejection fraction >= institutional lower limit of normal (ILLN) by multi gated acquisition (MUGA) scan or 2-dimensional (D) echocardiogram (ECHO) within 42 days prior to registrationXx_NEWLINE_xXCardiac ejection fraction at or above the lower limit of normal as measured by multigated radionuclide angiography (MUGA) scans or echocardiogram documented =< 3 months prior to registrationXx_NEWLINE_xXAbnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] <40% and shortening fraction <15%). Appropriate correction to be used, if a MUGA is performed.Xx_NEWLINE_xXCLINICAL/LABORATORY CRITERIA: Patients must have a left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (ILLN) by echocardiography (ECHO) or multi-gated acquisition scan (MUGA) within 42 days prior to registrationXx_NEWLINE_xXHemodynamically stable and Left Ventricle Ejection Fraction (LVEF) ? 45% confirmed by echocardiogram or Multigated Radionuclide Angiography (MUGA)Xx_NEWLINE_xXAbnormal left ventricular ejection fraction (LVEF; <50%) or echocardiogram ECHO or multiple gated acquisition scan (MUGA). [Applies to Phase 1 only; ECHO/MUGA scans are not performed in Phase 2.]Xx_NEWLINE_xXLeft ventricular ejection fraction < 50% on echocardiogram or multi-gated acquisition (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ?50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ? 40% as measured by MUGA scan or 2-D ECHO within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead ECGXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ? 40% as measured by MUGA scan or 2-D ECHO within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead ECGXx_NEWLINE_xXPatients must have a left ventricular ejection fraction >= lower limit of normal by echocardiogram (ECHO) or multigated acquisition scan (MUGA)Xx_NEWLINE_xXLeft Ventricular Shortening Fraction (LVSF) ? 28% confirmed by echocardiogram (ECHO), or Left Ventricular Ejection Fraction (LVEF) ? 45% confirmed by echocardiogram or Multiple Uptake Gated Acquisition (MUGA).Xx_NEWLINE_xXHave left ventricular ejection fraction by multigated acquisition scan (MUGA) scan or 2D-ECHO within normal limits for the institutionXx_NEWLINE_xXPatients with a known history of congestive heart failure or cardiac ejection fraction < 50% (or less than institutional normal limits); echocardiogram (ECHO) or multigated acquisition scan (MUGA) is not required prior to enrollment; for patients assigned to the chemotherapy arm, an ECHO or MUGA should be done within 6 months of day 1 of gemcitabine-docetaxel treatment\r\n* Patients who enroll on study and are randomized to Regimen I (chemotherapy ) and then are found on baseline ECHO or MUGA to have cardiac ejection fraction < 50% or below institutional normal will remain ON study; such patients will receive gemcitabine + docetaxel for 4 cycles but will NOT receive any doxorubicin treatment; they will continue treatment follow-up as outlined for all patients assigned to Regimen IXx_NEWLINE_xXLeft ventricular ejection fraction >= lower limit of normal as assessed by echocardiogram or multigated acquisition scanXx_NEWLINE_xXPatients who received prior therapy with anthracyclines should have a baseline multigated acquisition scan (MUGA) or echocardiogram (echo) with a normal ejection fraction within 28 days prior to randomizationXx_NEWLINE_xXEjection fraction of >= 45% by either multi-gated acquisition (MUGA) scan or echocardiogram (ECHO)Xx_NEWLINE_xXHas a pre-study echocardiogram or multi-gated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institutional lower limit of normal within one month of initiating therapy.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 50% as determined by Multiple Gated acquisition scan (MUGA) or echocardiogram (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) must be equal to or greater than 50%, as measured by multi gated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXleft ventricular ejection fraction (LVEF) < 45% as determined by multigated acquisition (MUGA) scan or echocardiography (ECHO).Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan within normal range (according to institutional standards).Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) greater than 50% on echocardiography or multiple gated acquisition (MUGA) scan.Xx_NEWLINE_xXPatients with a left ventricular cardiac ejection fraction < 50% as assessed by an echocardiogram or MUGA scan or prolonged QTc interval of Grade 2 or higher or history of prolonged QTc interval from other drugs.Xx_NEWLINE_xXPatient has a Left Ventricular Ejection Fraction (LVEF) < 50 % as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screeningXx_NEWLINE_xXFor participants who will be receiving CHOP: left ventricular ejection fraction (LVEF) <50% by multiple-gated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXPatients must have a left ventricular ejection fraction (LVEF) >= 50% by (either multigated acquisition [MUGA] or 2-dimensional [2-D] echocardiogram) within 28 days of registrationXx_NEWLINE_xXSubjects with major cardiac illness multi-gated acquisition scan (MUGA) or echocardiogram (ECHO) < 50% ejection fraction (EF)Xx_NEWLINE_xXCardiac ejection fraction >= 50% by echocardiography or multi gated acquisition (MUGA) (when left ventricular ejection fraction [LVEF] expressed as a range, at least the upper limit should include 50%)Xx_NEWLINE_xXBaseline multi gated acquisition scan (MUGA) or echocardiogram scans with left ventricular ejection fraction (LVEF) of > 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40% as confirmed by echocardiogram (ECHO)/multigated acquisition (MUGA)Xx_NEWLINE_xXPatient must have adequate cardiac function (left ventricular ejection fraction [LVEF] >= 50% as determined by a multigated acquisition [MUGA] scan or echocardiogram; and corrected QT [QTc] interval =< 480 ms by Fridericia’s formula [QTcF])Xx_NEWLINE_xXCardiac left ventricular function with resting ejection fraction >50% as determined by echocardiogram (ECHO) or multigated acquisition scan (MUGA).Xx_NEWLINE_xXBaseline Left Ventricular Ejection Fraction (LVEF) >/= 55 percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA)Xx_NEWLINE_xXSubjects with multi gated acquisition scan (MUGA) < 50% ejection fraction (EF)Xx_NEWLINE_xXLeft ventricular ejection fraction less than (<) 50% as defined by multiple-gated acquisition (MUGA)Xx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram (ECHO) ORXx_NEWLINE_xXEjection fraction >= 50% by ECHO or gated radionuclide studyXx_NEWLINE_xXBaseline left ventricular ejection fraction (LVEF) greater than or equal to (>/=) 55 percent (%) measured by echocardiogram (ECHO) or Multiple-Gated Acquisition (MUGA) ScanXx_NEWLINE_xXShortening fraction >= 27% by echocardiogramXx_NEWLINE_xXEjection fraction >= 47% by radionuclide angiogram (multi gated acquisition scan [MUGA]); Note: the echocardiogram (or MUGA) may be done within 28 days prior to enrollmentXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% as assessed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) documented =< 28 days prior to registrationXx_NEWLINE_xXBaseline left ventricular ejection fraction LVEF >= 50% as evaluated by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)Xx_NEWLINE_xXPatients older than 70 years of age should have left ventricular ejection fraction within ULN by multigated acquisition (MUGA) or 2-dimensional (2D) echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction > 45% by either multi gated acquisition scan (MUGA) scan or echocardiogram; if ejection fraction (EF) is < 50%, a cardiology consult should be placed and echocardiogram performed if not already doneXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 50% as determined by a multigated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) defined by multigated acquisition (MUGA) or echocardiogram which is below the institutional lower limit of normal prior to starting study treatmentXx_NEWLINE_xXAbnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] < 55%); appropriate correction to be used if a MUGA is performedXx_NEWLINE_xXHas a left ventricular ejection fraction (LVEF) within the normal institutional range (or >= 50%) based on an echocardiogram (ECHO) or multigated acquisition scan (MUGA), completed within 4 weeks prior to day one of treatmentXx_NEWLINE_xXEjection fraction of < 45% by either multi gated acquisition scan (MUGA) or echocardiogram (ECHO)Xx_NEWLINE_xXFor patients in stratum A, an echocardiogram (ECHO) or multi gated acquisition scan (MUGA) demonstrating ejection fraction (EF) > 50% is required within 28 days prior to study drug administrationXx_NEWLINE_xXBaseline ejection fraction ? 50% as assessed by echocardiogram or MUGA.Xx_NEWLINE_xXLeft ventricular ejection fraction of >= 40% by multi-gated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXBaseline ejection fraction >= 50% by multi gated acquisition scan (MUGA) scan or echocardiogram performed =< 60 days prior to registrationXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) must be equal to or greater than 40%, as measured by multi gated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXIntraventricular septal (IVS) thickness =< 25 mm (as determined by 2-dimensional [2D] echocardiography or cardiac magnetic resonance imaging [MRI]) (ejection fraction may also be assessed by a multi-gated acquisition [MUGA])Xx_NEWLINE_xXBaseline Left ventricular ejection fraction (LVEF) >=50% as measured by Echocardiogram (ECHO) or Multigated acquisition (MUGA) and above the testing institution's lower limit of normalXx_NEWLINE_xXPatients who have abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] < 50%); appropriate correction to be used if a MUGA is performedXx_NEWLINE_xXMust have an echocardiogram or multi gated acquisition scan (MUGA) indicating left ventricular ejection fraction (LVEF) >= 50% within 42 days prior to first dose of study drugXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) no more than 5 absolute percentage points below the institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration (i.e., if the institutional normal is 50%, subject's LVEF may be as low as 45% to be eligible for the study)Xx_NEWLINE_xXSubjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately 28 days of C1D1.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40% on 2-dimentional (2-D) transthoracic echocardiogram (ECHO); multigated acquisition scan (MUGA) is acceptableXx_NEWLINE_xXSubjects must have a multi gated acquisition scan (MUGA) and/or echocardiogram (ECHO) or cardiac magnetic resonance (MR); the required minimum standards include MUGA or ECHO or cardiac MR showing an ejection fraction (EF) of 40%; those with an EF 40-49% must also have a cardiologist consult and assist with managementXx_NEWLINE_xXAdequate cardiac function defined as left ventricular ejection fraction (LVEF) >= 40%\r\n* NOTE: 2-dimensional (2-D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation\r\n* Multigated acquisition scan (MUGA) is acceptable if ECHO is not availableXx_NEWLINE_xXCardiac ejection fraction >= 45% by echocardiography (transthoracic echocardiography) or multi gated acquisition scan (MUGA) scanXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) of at least 50% as determined by MUGA or echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower, as determined by echocardiogram or Multi Gated Acquisition Scan (MUGA) scanXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by echocardiogram or multigated acquisition scan (MUGA) documented within 4 weeks prior to first dose of study drug.Xx_NEWLINE_xXBaseline left ventricular ejection fraction (LVEF) >/=55% measured by echocardiogram (ECHO; preferred) or multiple-gated acquisition (MUGA) scansXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= institutional lower limit of normal by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA)Xx_NEWLINE_xXPatient has a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)Xx_NEWLINE_xXHave a 12-lead electrocardiogram (ECG) and echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed by the investigator or other qualified person to evaluate cardiac function prior to enrollment in the studyXx_NEWLINE_xXAdequate cardiac function, defined as left ventricular ejection fraction ? 40% as assessed by echocardiogram or multiple uptake gated acquisition scan performed within 30 days prior to determination of eligibilityXx_NEWLINE_xXLeft ventricular ejection fraction >= 50%, as determined by radionuclide ventriculogram (RVG) (multigated acquisition [MUGA]) or echocardiogram (ECHO) within 60 days prior to initiation of protocol therapyXx_NEWLINE_xXPatients must have adequate cardiac function as demonstrated by normal left ventricular ejection fraction (LVEF) >= the lower limit of normal for the facility on multi gated acquisition (MUGA) scan or echocardiogram (ECHO) within 3 months of enrollmentXx_NEWLINE_xXSubjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately 28 days of C1D1.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50%, as determined by radionucleoventilugrams (RVG) (multi-gated acquisition-MUGA) or echocardiogram (ECHO) within 28 days prior to initiation of protocol therapyXx_NEWLINE_xXPatient must have a left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition (MUGA) within 28 days prior to registrationXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) greater or equal to 50% at baseline as determined by either echocardiogram (ECHO) or multi gated acquisition scan (MUGA), or within the institution’s normal limitsXx_NEWLINE_xXLeft ventricular ejection fraction within institutional normal limits, as determined by echocardiography or multiple uptake gated acquisition (MUGA) scanXx_NEWLINE_xXNormal left ventricular ejection fraction on multigated acquisition scan (MUGA) or echocardiogram within the past 1 year prior to registration for patients with history of congestive heart failure and/or coronary disease requiring medications other than aspirin, or known prior exposure to anthracycline chemotherapyXx_NEWLINE_xXEjection fraction by echocardiogram (ECHO) or multigated acquisition scan (MUGA) of >= 40% performedXx_NEWLINE_xXEchocardiogram (Echo) or multi-gated acquisition scan (MUGA) with ejection fraction > 50%Xx_NEWLINE_xXEjection fraction on echocardiogram (Echo) or multi gated acquisition scan (MUGA) > 50%Xx_NEWLINE_xXAdequate cardiac function (left ventricular ejection fraction [LVEF] > 40%) as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed within 1 month of treatmentXx_NEWLINE_xXEjection fraction >= 45% as determined by transthoracic echocardiogram or multigated acquisition scan (MUGA)Xx_NEWLINE_xXCardiac ejection fraction >= lower limit of normal as determined by 2-dimensional (D) echocardiogram (echo) or multigated acquisition (MUGA) scan according to institutional standardsXx_NEWLINE_xXCardiac ejection fraction, as assessed by either multigated acquisition (MUGA) scan or echocardiogram, greater than or equal to 50%, within 28 days prior to registrationXx_NEWLINE_xXScreening Left ventricular ejection fraction (LVEF) >/= 50% on echocardiogram (ECHO) or multiple-gated acquisition (MUGA) after receiving neoadjuvant chemotherapy and no decrease in LVEF by more than 15% absolute points from the pre-chemotherapy LVEF. Or, if pre-chemotherapy LVEF was not assessed, the screening LVEF must be >/= 55% after completion of neoadjuvant chemotherapy.Xx_NEWLINE_xXAn echocardiogram (ECHO) or multiple gated acquisition (MUGA) demonstrating ejection fraction (EF) > 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)\r\n* Same method as used at baseline must be use throughout the study, ECHO is the preferred methodXx_NEWLINE_xXCardiac ejection fraction ? 50% by echocardiography or MUGAXx_NEWLINE_xXSubjects with an evaluation of cardiac function indicating normal function on MUGA scan (multiple gated acquisition scan) or other methodology; ANDXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) must be >= the lower limit of normal (LLN) per institutional standards by either echocardiography or radionuclide-based multiple gated acquisition (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) >= 45%Xx_NEWLINE_xXNormal cardiac function defined as either a MUGA or echocardiogram (ECHO) with left ventricular ejection fraction (LVEF) in normal institutional range (MUGA 50%; ECHO 55%)Xx_NEWLINE_xXShortening fraction >= 28% on screening echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction >= 50%, as determined by radionuclide ventriculograms (RVG) (multi-gated acquisition scan [MUGA]) or echocardiogram within 60 days prior to initiation of protocol therapyXx_NEWLINE_xXLeft ventricular ejection fraction >= 50%, as determined by RVG (MUGA) or echocardiogram within 60 days prior to initiation of extension phase therapy (all cohorts)Xx_NEWLINE_xXPatients must have a multi gated acquisition scan (MUGA) or echocardiogram within 90 days prior to starting treatment and the ejection fraction must be >= 45%Xx_NEWLINE_xXLeft ventricular ejection fraction estimated by multi gated acquisition scan (MUGA) scan or 2-dimensional (2D)-echocardiogram of at least 45% cardiology consult is recommended prior to enrollment if a history of coronary artery disease, congestive heart failure (CHF) with estimated left ventricular ejection fraction (LVEF) of < 50% or clinically significant arrhythmiaXx_NEWLINE_xXBaseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45% at rest (multi gated acquisition [MUGA] or echocardiogram [Echo])Xx_NEWLINE_xXImpaired cardiac function (left ventricular ejection fraction [LVEF] < 40%) as assessed by echocardiogram (ECHO) or multi gated acquisition (MUGA) scanXx_NEWLINE_xXCardiac: Left ventricular ejection fraction at rest ? 40% demonstrated by Multi Gated Acquisition Scan (MUGA) or echocardiogram. Patients with known heart disease must have a functional status no worse than American Heart Association Class I defined as patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.Xx_NEWLINE_xXNormal cardiac function as demonstrated by a left ventricular ejection fraction >= 50% on echocardiogram or multi gated acquisition (MUGA) scanXx_NEWLINE_xXEjection fraction < 50%, as determined by echocardiogram or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < institutional lower limit of normal (LLN) by ECHO (preferred) or MUGA scan at the time of transition to this study.Xx_NEWLINE_xXLeft ventricle ejection fraction (LVEF) >= 40%; 2-dimensional (D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multigated acquisition scan (MUGA) is acceptable if ECHO is not availableXx_NEWLINE_xXLeft ventricular ejection fraction >= 50% OR shortening fraction of >= 27% demonstrated on 2 dimensional (2D) echocardiogram or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXFor participants who will be receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP): left ventricular ejection fraction (LVEF) less than (<) 50% by multiple-gated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXAdequate cardiac function, defined by baseline LVEF greater than 50% by Multiple Gated Acquisition (MUGA) scan or echocardiogram.Xx_NEWLINE_xXLeft ventricular ejection fraction assessment (echocardiogram or multiple gated acquisition [MUGA] scan) performed within 4 weeks prior to study initiation, showing a left ventricular ejection fraction (LVEF) value >= lower limit of normal (LLN)Xx_NEWLINE_xXMultiple Gated Acquisition (MUGA) or echocardiogram (ECHO) must demonstrate LVEF >/= 45%.Xx_NEWLINE_xXLeft ventricular ejection fraction >= 50% by echocardiogram (ECHO) or multi-gated acquisition scan (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction measured by multi-gated acquisition scan (MUGA) or echocardiogram (ECHO) >= 45%Xx_NEWLINE_xXCardiac ejection fraction >= 50% as measured by echocardiogram of multiple gated acquisition scan (MUGA) scanXx_NEWLINE_xXBaseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normalXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) greater than or equal to 50% on technetium-99m pertechnetate radionuclide cineangiography (multi gated acquisition scan [MUGA]) or echocardiogramXx_NEWLINE_xXSubjects must have a MUGA scan or echo with LVEF >50%Xx_NEWLINE_xXLeft ventricular ejection fraction >= the lower limit of normal by echocardiogram (ECHO) or multigated acquisition scan (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% (as assessed by echocardiography [ECHO] or multigated acquisition [MUGA]) documented within 4 weeks prior to first dose of study treatmentXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40% within 28 days prior to registration, evaluated by 2-dimensional (D) transthoracic echocardiogram (ECHO) or, if ECHO is not available, by multi-gated acquisition (MUGA) scanXx_NEWLINE_xXHistory of significant cardiovascular disease, even if currently controlled, or who has signs or symptoms suggesting impaired left ventricular function in the judgment of the investigator must have a screening left ventricular ejection fraction (LVEF) evaluation by echocardiogram (ECHO) or multi gated acquisition scan (MUGA); patients with LVEF measurements below local institutional lower limit of normal or less than 50% will not be eligibleXx_NEWLINE_xXAdequate cardiac function (left ventricular ejection fraction [LVEF] >= 40%) as assessed by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) or other similar cardiac imaging performed within 1 month of enrollmentXx_NEWLINE_xXEjection fraction (EF) > 50% by multi gated acquisition scan (MUGA)Xx_NEWLINE_xXEligible for SCT with left ventricular ejection fraction (LVEF) >= 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO), and diffusing capacity > 50% predicted by pulmonary function testingXx_NEWLINE_xXLeft ventricular ejection fraction > 45% by either multigated acquisition scan (MUGA) or 2-dimensional (2-D) echocardiogram (echo), obtained within 28 days of enrollment; patients who have a prior cumulative anthracycline dose greater than 450 mg/m^2 will also have a cardiology consult to determine if further anthracycline administration is an absolute contraindication in patients who may require induction chemotherapy with EPOCH-FXx_NEWLINE_xXPatients must have an echocardiogram or multi gated acquisition (MUGA) scan; if the ejection fraction is < 40%, the patient will not be eligible; if the ejection fraction is 40-50%, patients must have an exercise echocardiogram or dobutamine-echocardiogram (echo) with a normal response to exerciseXx_NEWLINE_xXCardiac ejection fraction (EF) < 40% on multi-gated acquisition (MUGA) scan or cardiac echocardiogram (echo) (or if unable to obtain ejection fraction, shortening fraction of < 26%); patients with active or a history of cardiac disease should be evaluated with appropriate cardiac studies and/or consult; ejection fraction is required if age > 50 years or there is a history of anthracyclines or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologistXx_NEWLINE_xXPatients must have a shortening fraction greater than or equal to 27% by echocardiogram, OR ejection fraction greater than or equal to 50% by radionuclide angiogram (multigated acquisition [MUGA])Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) AND at least 50%; LVEF can be assessed by either echocardiogram (ECHO) or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXLVEF < 45% by echocardiogramXx_NEWLINE_xXEjection fraction (EF) of at least >= 40% by multigated acquisition (MUGA) or echocardiography (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% as determined by echocardiogram or multi-gated acquisition scan (MUGA)Xx_NEWLINE_xXLVEF (left ventricular ejection fraction) of 45% or less as determined by MUGA (multi-gated acquisition) or ECHO (Echocardiogram)Xx_NEWLINE_xXPatient must have a shortening fraction ? 27% by Echo or an ejection fraction ? 50% by MUGA. Reproductive FunctionXx_NEWLINE_xXNormal cardiac left ventricular ejection fraction (LVEF) by multiple-gated acquisition (MUGA) scan or transthoracic echocardiogramXx_NEWLINE_xXCardiac ejection fraction >= 50% by multi-gated acquisition (MUGA) scan and/or by echocardiogramXx_NEWLINE_xXAdequate left ventricular function with ejection fraction >= 40% by echocardiogram or multi-gated acquisition scan (MUGA) scanXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) by echocardiogram or multiple gated acquisition (MUGA) scan ? the lower limit of normal (LLN) for the InstitutionXx_NEWLINE_xXPatients have impaired cardiac function or clinically significant cardiac diseases, including any of the following: a) history or presence of serious uncontrolled ventricular arrhythmias or presence of atrial fibrillation; b) clinically significant resting bradycardia (< 50 beats per minute); c) left ventricular ejection fraction (LVEF) assessed by 2-dimensional (D) echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) < 45%; d) pericardial effusionXx_NEWLINE_xXAdequate cardiac function (left ventricular ejection fraction [LVEF] ?50% measured by echocardiography or multi-gated acquisition [MUGA] scan)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) within institutional range of normal as measured by echocardiogram (ECHO); multigated acquisition (MUGA) scans will be accepted in cases where an echocardiogram cannot be performed or is inconclusive (LVEF of > 50% required if normal range LVEF is not provided by institution)Xx_NEWLINE_xXBaseline (< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (MUGA scan) or echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% as determined by a multigated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 45% as determined by MUGA scan or ECHOXx_NEWLINE_xXPatients with a cardiac ejection fraction (as measured by either multi gated acquisition scan [MUGA] or echocardiogram) less than 40%Xx_NEWLINE_xXMeasured cardiac ejection fraction > or = to 50% or the institutional lower limit of normal by echocardiogram or MUGA scan.Xx_NEWLINE_xXCardiac ejection fraction >= 40% (multigated acquisition [MUGA] or echocardiogram); for patients with significant risk factors for coronary artery disease (CAD) (including family history, hypertension, and/or dyslipidemia), or age > 50, stress echo or stress thallium testing is requiredXx_NEWLINE_xXNormal (greater than 50%) left ventricular ejection fraction (LVEF) by multi gated acquisition (MUGA) scan or echocardiographyXx_NEWLINE_xXBaseline left ventricular ejection fraction (LVEF) less than (<) 50%, documented by echocardiography, multiple-gated radionuclide angiography (MUGA) scan, or cardiac magnetic resonance imaging (MRI)Xx_NEWLINE_xXLeft ventricular ejection fraction by multigated acquisition scan (MUGA) or echocardiogram >= 55% for patients with triple negative breast cancer; >= upper limit of institutional normal for patient with HR+ breast cancer within 7 days of treatment initiationXx_NEWLINE_xXLeft ventricular ejection fraction =< 50% as demonstrated by echocardiogram or multigated acquisition scan (MUGA)Xx_NEWLINE_xXPatients with left ventricular ejection fraction < 50% on echocardiogram or multigated acquisition scan will be excludedXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 45% as determined by MUGA scan or echocardiogram (ECHO).Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45 % (by multigated acquisition scan [MUGA] or echocardiography)Xx_NEWLINE_xXBaseline multigated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXLeft ventricular ejection fraction >= 45% by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXEjection fraction by multi gated acquisition scan (MUGA) scan or echocardiogram >= lower limit of institutional normalXx_NEWLINE_xXLeft Ventricular Ejection Fraction (LVEF) < 40% as determined by Multiple Gated Acquisition (MUGA) scan or echocardiogram (ECHO).Xx_NEWLINE_xXNormal left ventricular ejection fraction on screening assessed by transthoracic echocardiogram or multiple gated acquisition (MUGA) scanXx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, orXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) determined by 2 dimensional echocardiogram (2D Echo) or multi-gated acquisition scan (MUGA) ? 50% or ? local institutional lower limit normal (LLN) whichever is higher.Xx_NEWLINE_xXCardiac ejection fraction >= 40% (by either cardiac echocardiogram [echo] or multigated acquisition [MUGA] scan); documentation of recent (=< 6 months from screening) outside reports is acceptableXx_NEWLINE_xXBaseline of Left Ventricular Ejection Fraction (LVEF) ?50% measured by echocardiography (ECHO) or multi-gated acquisition scan (MUGA)Xx_NEWLINE_xXAdequate organ function defined by the screening laboratory inclusion listed below and Left Ventricular Ejection Fraction (LVEF) ? 45% confirmed by ECHO or multigated acquisition (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)Xx_NEWLINE_xXPatients with a left ventricular cardiac ejection fraction < 50% as assessed by an echocardiogram or MUGA scanXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40% (multigated acquisition scan [MUGA] or echocardiogram)Xx_NEWLINE_xXLeft ventricular ejection fraction as measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) should be >= 40%Xx_NEWLINE_xXAll patients must have an echo or multigated acquisition (MUGA) scan showing ejection fraction (EF) > 50% and normal troponin and creatine kinase MB (CK MB) performed within 90 days of starting treatmentXx_NEWLINE_xXCardiac ejection fraction >= 50%, as measured by echocardiography (ECHO) or multigated acquisition scan (MUGA)Xx_NEWLINE_xXBaseline (< 1 month before treatment) cardiac left ventricular function with resting ejection fraction of less than 50% measured by multigated blood pool imaging of the heart (multi gated acquisition scan [MUGA] scan) or echocardiogramXx_NEWLINE_xXCardiac ejection fraction ?50% by ECHO or MUGAXx_NEWLINE_xXCardiac Function: Patient must have a shortening fraction (SF) of > 27% or an ejection fraction (EF) of > 50% by echocardiogram or MUGA scan.Xx_NEWLINE_xXShortening fraction of >= 27% by echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% as determined by a multigated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXSubjects with a left ventricular cardiac ejection fraction < 50% as assessed by an echocardiogram or MUGA scanXx_NEWLINE_xXLeft ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA)Xx_NEWLINE_xXSymptomatic left ventricular dysfunction or baseline left ventricular ejection fraction (LVEF) by multigated acquisition scan (MUGA) or echocardiogram (ECHO) =< 50% lower limit of institutional normal (LLN)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) > 40% (by echocardiogram [ECHO] or multigated acquisition scan [MUGA])Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45% by multi gated acquisition (MUGA) scan or echocardiogram (ECHO)Xx_NEWLINE_xXCardiac ejection fraction (EF) >= 45% by 2-dimensional echocardiogram (2D-Echo)Xx_NEWLINE_xXAdequate cardiac function with LVEF >=50% as assessed by echocardiogram (ECHO) or Multi Gated Acquisition Scan (MUGA.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% by either echocardiogram (ECHO) or multigated acquisition scan (MUGA)Xx_NEWLINE_xXScreening calculated ejection fraction greater than or equal to the institutional lower limit of normal by multiple gated acquisition (MUGA) scan or by echocardiogram (ECHO); a MUGA is preferred because of greater reproducibilityXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40%, assessed within 28 days prior to registration, e.g. by multi gated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modalityXx_NEWLINE_xXPatients must have either echocardiogram (ECHO) or multi gated acquisition scan (MUGA) with ejection fraction >= 45% within 28 days prior to registrationXx_NEWLINE_xXCardiac ejection fraction · 40% (by either cardiac echocardiogram [ECHO] or multi gated acquisition [MUGA] scan)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition scan (MUGA) or echocardiogram (ECHO).Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 40% within 30 days before cycle 1 day 1; 2-dimensional (2-D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multigated acquisition (MUGA) is acceptable if ECHO is not availableXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) less than 50 percent as assessed by echocardiography (or multi-gated acquisition) performed at screeningXx_NEWLINE_xXPatients must have a pre-study echocardiogram or multigated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institution lower limit of normal within one month prior to start of study.Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) ?institutional lower limit of normal as measured by multigated acquisition scan (MUGA) or 2-dimensional (2-D) echocardiography (ECHO) within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead electrocardiogram (ECG)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) greater than or equal to 50% on technetium-99m pertechnetate radionuclide cineangiography (multi gate acquisition scan [MUGA]) or echocardiogramXx_NEWLINE_xXAll patients must have an left ventricular ejection fraction (LVEF) measurement of at least 50% by echocardiogram (ECHO) or multigated acquisition scan (MUGA) (if clinically indicated) within 14 days prior to registration; the method used for LVEF assessment in an individual subject must be the same throughout the trialXx_NEWLINE_xXBaseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normalXx_NEWLINE_xXLVEF (measured by Echocardiogram) > 50%Xx_NEWLINE_xXBaseline multi gated acquisition (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 45%Xx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram or ejection fraction >= 45% by gated radionuclide studyXx_NEWLINE_xXLVEF <45% as determined by MUGA or echoXx_NEWLINE_xXNormal (greater than 50%) left ventricular ejection fraction (LVEF) by multiple gated acquisition (MUGA) scan or echocardiographyXx_NEWLINE_xXShortening fraction >= 27% by echocardiogram orXx_NEWLINE_xXBaseline multiple gated acquisition (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 50%Xx_NEWLINE_xXPatients with prior anthracycline exposure must have a baseline multi gated acquisition scan (MUGA) or echocardiogram prior to study entryXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) as assessed by echocardiography or multigated acquisition (MUGA) scanXx_NEWLINE_xXNormal cardiac function (ejection fraction >= lower limit of normal) as determined by multi-gated acquisition scan (MUGA) or echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction > 40% (multi gated acquisition scan [MUGA] or echocardiogram [echo]) within 28 days of enrollmentXx_NEWLINE_xXShortening fraction of >= 25% by echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% by multiple gated acquisition scan (MUGA) or cardiac echocardiogram (ECHO), prior for any patient to be treated with R-CHOPXx_NEWLINE_xXMUGA/Echocardiogram Left Ventricular Ejection Fraction < 50%.Xx_NEWLINE_xXCardiac left ventricular ejection fraction > 40% by echocardiogram or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXShortening fraction of >= 27% by echocardiogram, or if shortening fraction abnormal, ejection fraction of >= 55% by gated radionuclide study or echocardiogram; note: the echocardiogram or gated radionuclide study must be performed within 4 weeks prior to enrollmentXx_NEWLINE_xXCardiac ejection fraction ?50% by ECHO or MUGAXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) be at least >= institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administrationXx_NEWLINE_xXLeft ventricular ejection fraction > 50% on echocardiography or multigated acquisition (ECHO/MUGA) scanXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram (ECHO)Xx_NEWLINE_xXAll patients must have an echo or multi gated acquisition scan (MUGA) scan showing ejection fraction (EF) > 50% and normal troponin and creatine kinase (CK) myoglobin binding (MB) (echo may be done at the time of stress test as a stress echo); within 6 months of starting treatment; however if the patient has received cardiotoxic chemotherapy such as Adriamycin, they must have had an echo or MUGA scan since completing this treatmentXx_NEWLINE_xXEchocardiogram or multi gated acquisition (MUGA) scan with ejection fraction within normal institution limits within 28 days of registrationXx_NEWLINE_xXLeft ventricular ejection fraction >= 40% by echocardiogram (ECHO)/multi gated acquisition scan (MUGA)Xx_NEWLINE_xXMeeting institutional criteria for allo-HCT; ejection fraction by echocardiogram or multi-gated acquisition scan (MUGA) > 40%, pulmonary function test with adjusted diffusion capacity of the lung for carbon monoxide (DLCO) >= 60%Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% by MUGA (multi gated acquisition) scan or echocardiogramXx_NEWLINE_xXShortening fraction on echocardiogram > 28%Xx_NEWLINE_xXEjection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 45%Xx_NEWLINE_xXCardiac ejection fraction < 50 (using motion [M]-Mode if assessment is done by echocardiogram [ECHO])Xx_NEWLINE_xXUncontrolled or severe cardiovascular disease or left ventricular ejection fraction < 50% as determined by echocardiogram or multigated acquisition scan (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) by echocardiogram or multi gated acquisition scan (MUGA) within institutional normal limitsXx_NEWLINE_xXSubjects should have left ventricular ejection fraction (LVEF) >= 50% by echocardiogram or multi gated acquisition (MUGA) scan performed within 4 weeks prior to treatment initiationXx_NEWLINE_xXEjection fraction < 50% on echocardiogram (ECHO) or MUGAXx_NEWLINE_xXLVEF ? 50% by MUGA or ECHOXx_NEWLINE_xXA resting ejection fraction of 50% or greater which increases with exercise as demonstrated by resting/exercise multigated acquisition (MUGA) or ejection fraction of 50% or greater by echocardiogramXx_NEWLINE_xXA cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of 50% established by multi gated acquisition scan (MUGA) or echocardiogramXx_NEWLINE_xXCardiac function: Ejection fraction at rest ? 45.0% or shortening fraction of ? 27.0% by echocardiogram or radionuclide scan (MUGA).Xx_NEWLINE_xXLVEF >50%, or an LVEF within the normal limits of the institution's specific testing (MUGA or ECHO)Xx_NEWLINE_xXPatients with an ejection fraction < 45% assessed by MUGA or ---ECHO within 28 days prior to starting study cycle 1 (of midostaurin or control group)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) results must be >= lower limit of normal (LLN) for institution performing based on results from the multi-gated acquisition (MUGA) or echocardiogram (ECHO) done at baselineXx_NEWLINE_xXLeft ventricular ejection fraction must be > 45% assessed by multi-gated acquisition scan (MUGA) scan or echocardiogram; no myocardial infarction within 6 months of transplant evaluationXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) greater or equal to 50% at baseline as determined by either echocardiogram (ECHO) or multigated acquisition (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 50% by multigated acquisition scan (MUGA) scan or echocardiogram (ECHO)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45% by multigated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXShortening fraction > 27% by echocardiogram, orXx_NEWLINE_xXShortening fraction of > 25% by echocardiogram, orXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >= 45% by multi gated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXCardiac ejection fraction < 30% on multi gated acquisition scan (MUGA) scan or cardiac echocardiogram (echo) or active symptomatic coronary artery disease; patients with cardiac disease should be evaluated with appropriate cardiac studies and/or cardiology consultation as clinically indicatedXx_NEWLINE_xXLeft ventricular ejection fraction < 45% (evaluated by echocardiogram or MUGA scan)Xx_NEWLINE_xXLeft ventricular ejection fraction < 50% (evaluated by echocardiogram or MUGA)Xx_NEWLINE_xXSubjects with major cardiac illness multi-gated acquisition scan (MUGA) < 50% ejection fraction (EF)Xx_NEWLINE_xXPatients must have left ventricular ejection fraction (LVEF) > 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within 4 weeks prior to registrationXx_NEWLINE_xXLeft ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXSubject has left ventricular ejection fraction (LVEF) ? 50%, or below institution's lower limit of normal (whichever is lower) by echocardiogram (ECHO) or multigated acquisition (MUGA) scan.Xx_NEWLINE_xXHave current or a history of congestive heart failure New York Heart Association (NYHA) class 3 or 4, or any history of documented diastolic or systolic dysfunction (left ventricular ejection fraction [LVEF] < 40%, as measured by multigated acquisition [MUGA] scan or echocardiogram)Xx_NEWLINE_xXAdequate cardiac function as defined by left ventricular ejection fraction (LVEF) >= 50% on echocardiogram or multi-gated acquisition scan (MUGA)Xx_NEWLINE_xXPatients must have adequate cardiac function; left ventricular ejection fraction (LVEF) >= 50% as determined by multi gated acquisition (MUGA) scan or echocardiogramXx_NEWLINE_xXLeft ventricular ejection fraction >= 50% by echocardiogram (ECHO) (preferred) or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXHas left ventricular ejection fraction (LVEF) < 45% by either echocardiogram (ECHO) or multigated acquisition scan (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction >= institutional lower limit of normal by multi-gated acquisition (MUGA) scan or echocardiogram within 30 days of first protocol treatmentXx_NEWLINE_xXAbnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] < 55%); appropriate correction to be used if a MUGA is performedXx_NEWLINE_xXCardiac ejection fraction >50% (by echocardiogram or MUGA) within 15 days of enrollmentXx_NEWLINE_xXEstimated cardiac ejection fraction >= 50% by echocardiogram or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXThe patient’s estimated cardiac ejection fraction is < 50% by echocardiogram or MUGAXx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) >50% on echocardiography or multiple-gate acquisition (MUGA) scan.Xx_NEWLINE_xXGROUP 2 (trametinib arm): Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXEjection fraction >= lower limit of normal (LLN) by echocardiogram (ECHO) (preferred) or multi gated acquisition scan (MUGA)Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) by echocardiography (ECHO) or multiplegated acquisition (MUGA) within normal range (according to institutional standards).Xx_NEWLINE_xXLeft ventricular ejection fraction (LVEF) <50 percent (%) as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks before receiving the first dose of study drug.Xx_NEWLINE_xX